Alba Gigante

Alba Gigante

Auto-generated profile, based on publicly available information

Alba Gigante

Department of Organic Chemistry University of Duisburg Essen Universitätstr. 7 45141 Essen Germany

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 August 2016 in Scientific Reports
Verified
Journal Article
Open access
Leen DelangLeen Delang
Leen Delang
CLC. Li
C. Li
ATA. Tas
A. Tas
GQG. Quérat
G. Quérat
IAI. C. Albulescu
I. C. Albulescu
JNJohan Hendrik Neyts
Johan Hendrik Neyts
The chikungunya virus (CHIKV) has become a substantial global health threat due to its massive re-emergence, the considerable disease burden and the lack of vaccines or therapeutics. We discovered a novel class of small molecules ([1,2,3]triazolo[4,5-d]pyrimidin-7(6H)-ones) with potent in vitro activity against CHIKV isolates from different geographical regions. Drug-resistant variants were selected and these carried a P34S substitution in non-structural protein 1 (nsP1), the main enzyme involved in alphavirus RNA capping. Biochemical assays using nsP1 of the related Venezuelan equine encephalitis virus revealed that the compounds specifically inhibit the guanylylation of nsP1. This is, to the best of our knowledge, the first report demonstrating that the alphavirus capping machinery is an excellent antiviral drug target. Considering the lack of options to treat CHIKV infections, this series of compounds with their unique (alphavirus-specific) target offers promise for the development of therapy for CHIKV infections.

6 May 2014 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
AGAlba Gigante
Alba Gigante
MCMaría-Dolores Canela
María-Dolores Canela
Leen DelangLeen Delang
Leen Delang
EPEva María Priego
Eva María Priego
MCMaría-Jose Camarasa
María-Jose Camarasa
María-Jesús Pérez-PérezMaría-Jesús Pérez-Pérez
María-Jesús Pérez-Pérez

5 December 2014 in Circulation Research
Verified
Journal Article
Closed access
PDF file
WLWei Li
Wei Li
AGAlba Gigante
Alba Gigante
María-Jesús Pérez-PérezMaría-Jesús Pérez-Pérez
María-Jesús Pérez-Pérez
HYHong Yue
Hong Yue
MHMichio Hirano
Michio Hirano
RSRoy L. Silverstein
Roy L. Silverstein
Rationale : Platelets contain abundant thymidine phosphorylase (TYMP), which is highly expressed in diseases with high risk of thrombosis, such as atherosclerosis and type II diabetes mellitus. Objective : To test the hypothesis that TYMP participates in platelet signaling and promotes thrombosis. Methods and Results : By using a ferric chloride (FeCl 3 )–induced carotid artery injury thrombosis model, we found time to blood flow cessation was significantly prolonged in Tymp −/− and Tymp +/− mice compared with wild-type mice. Bone marrow transplantation and platelet transfusion studies demonstrated that platelet TYMP was responsible for the antithrombotic phenomenon in the TYMP-deficient mice. Collagen-, collagen-related peptide–, adenosine diphosphate-, or thrombin-induced platelet aggregation were significantly attenuated in Tymp +/− and Tymp −/− platelets, and in wild type or human platelets pretreated with TYMP inhibitor KIN59. Tymp deficiency also significantly decreased agonist-induced P-selectin expression. TYMP contains an N-terminal SH3 domain-binding proline-rich motif and forms a complex with the tyrosine kinases Lyn, Fyn, and Yes in platelets. TYMP-associated Lyn was inactive in resting platelets, and TYMP trapped and diminished active Lyn after collagen stimulation. Tymp/Lyn double haploinsufficiency diminished the antithrombotic phenotype of Tymp +/− mice. TYMP deletion or inhibition of TYMP with KIN59 dramatically increased platelet-endothelial cell adhesion molecule 1 tyrosine phosphorylation and diminished collagen-related peptide– or collagen-induced AKT phosphorylation. In vivo administration of KIN59 significantly inhibited FeCl 3 -induced carotid artery thrombosis without affecting hemostasis. Conclusions : TYMP participates in multiple platelet signaling pathways and regulates platelet activation and thrombosis. Targeting TYMP might be a novel antiplatelet and antithrombosis therapy.

1 August 2017 in Antiviral Research
Verified
Journal Article
Open access
AGAlba Gigante
Alba Gigante
AGAsier Gómez-SanJuan
Asier Gómez-SanJuan
Leen DelangLeen Delang
Leen Delang
CLChangqing Li
Changqing Li
OBOskía Bueno
Oskía Bueno
María-Jesús Pérez-PérezMaría-Jesús Pérez-Pérez
María-Jesús Pérez-Pérez
Chikungunya virus (CHIKV) is a re-emerging alphavirus transmitted to humans by Aedes mosquitoes. Since 2005, CHIKV has been spreading worldwide resulting in epidemics in Africa, the Indian Ocean islands, Asia and more recently in the Americas. CHIKV is thus considered as a global health concern. There is no specific vaccine or drug available for the treatment of this incapacitating viral infection. We previously identified 3-aryl-[1,2,3]triazolo[4,5-d]pyrimidin-7(6H)-ones as selective inhibitors of CHIKV replication and proposed the viral capping enzyme nsP1 as a target. This work describes the synthesis of novel series of related compounds carrying at the aryl moiety a methylketone and related oximes combined with an ethyl or an ethyl-mimic at 5-position of the triazolopyrimidinone. These compounds have shown antiviral activity against different CHIKV isolates in the very low μM range based on both virus yield reduction and virus-induced cell-killing inhibition assays. Moreover, these antivirals inhibit the in vitro guanylylation of alphavirus nsP1, as determined by Western blot using an anti-cap antibody. Thus, the data obtained seem to indicate that the anti-CHIKV activity might be related to the inhibition of this crucial step in the viral RNA capping machinery.

16 August 2019 in MedChemComm
Verified
Journal Article
Closed access
PDF file
AGA. Gigante
A. Gigante
MLM. Li
M. Li
SJS. Junghänel
S. Junghänel
CHC. Hirschhäuser
C. Hirschhäuser
SKShirley K. Knauer
Shirley K. Knauer
CSC. Schmuck
C. Schmuck
Hybrid vectors are a remarkable strategy to address the current challenges in gene delivery.

1 April 2012 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
PDF file
SLSandra Liekens
Sandra Liekens
Annelies BronckaersAnnelies Bronckaers
Annelies Bronckaers
MBMirella Belleri
Mirella Belleri
ABAntonella Bugatti
Antonella Bugatti
RSRebecca Sienaert
Rebecca Sienaert
Marco PrestaMarco Presta
Marco Presta
5′-O-Tritylinosine (KIN59) is an allosteric inhibitor of the angiogenic enzyme thymidine phosphorylase. Previous observations showed the capacity of KIN59 to abrogate thymidine phosphorylase–induced as well as developmental angiogenesis in the chicken chorioallantoic membrane (CAM) assay. Here, we show that KIN59 also inhibits the angiogenic response triggered by fibroblast growth factor-2 (FGF2) but not by VEGF in the CAM assay. Immunohistochemical and reverse transcriptase PCR analyses revealed that the expression of laminin, the major proteoglycan of the basement membrane of blood vessels, is downregulated by KIN59 administration in control as well as in thymidine phosphorylase- or FGF2-treated CAMs, but not in CAMs treated with VEGF. Also, KIN59 abrogated FGF2-induced endothelial cell proliferation, FGF receptor activation, and Akt signaling in vitro with no effect on VEGF-stimulated biologic responses. Accordingly, KIN59 inhibited the binding of FGF2 to FGF receptor-1 (FGFR1), thus preventing the formation of productive heparan sulphate proteoglycan/FGF2/FGFR1 ternary complexes, without affecting heparin interaction. In keeping with these observations, systemic administration of KIN59 inhibited the growth and neovascularization of subcutaneous tumors induced by FGF2-transformed endothelial cells injected in immunodeficient nude mice. Taken together, the data indicate that the thymidine phosphorylase inhibitor KIN59 is endowed with a significant FGF2 antagonist activity, thus representing a promising lead compound for the design of multitargeted antiangiogenic cancer drugs. Mol Cancer Ther; 11(4); 817–29. ©2012 AACR.